Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer

Ashrafizadeh, M. and Hushmandi, K. and Moghadam, E.R. and Zarrin, V. and Kashani, S.H. and Bokaie, S. and Najafi, M. and Tavakol, S. and Mohammadinejad, R. and Nabavi, N. and Hsieh, C.-L. and Zarepour, A. and Zare, E.N. and Zarrabi, A. and Makvandi, P. (2020) Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering, 7 (3). pp. 1-40.

Full text not available from this repository.
Official URL:


Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treatments. Patients with PCa are commonly diagnosed in advanced stages due to the lack of symptoms in the early stages. Recently, the research focus was directed toward gene editing in cancer therapy. Small interfering RNA (siRNA) intervention is considered as a powerful tool for gene silencing (knockdown), enabling the suppression of oncogene factors in cancer. This strategy is applied to the treatment of various cancers including PCa. The siRNA can inhibit proliferation and invasion of PCa cells and is able to promote the anti-tumor activity of chemotherapeutic agents. However, the o-target eects of siRNA therapy remarkably reduce its ecacy in PCa therapy. To date, various carriers were designed to improve the delivery of siRNA and, among them, nanoparticles are of importance. Nanoparticles enable the targeted delivery of siRNAs and enhance their potential in the downregulation of target genes of interest. Additionally, nanoparticles can provide a platform for the co-delivery of siRNAs and anti-tumor drugs, resulting in decreased growth and migration of PCa cells. The ecacy, specificity, and delivery of siRNAs are comprehensively discussed in this review to direct further studies toward using siRNAs and their nanoscale-delivery systems in PCa therapy and perhaps other cancer types. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Item Type: Article
Additional Information: cited By 3
Subjects: WJ Urogenital System
QZ Pathology
Depositing User: eprints admin
Date Deposited: 26 May 2021 06:41
Last Modified: 26 May 2021 06:41

Actions (login required)

View Item View Item